View source for Abbott Laboratories

{{short description|American global medical devices and health care products company}}
{{Redirect|Abbott (company)|other uses|Abbott (disambiguation)}}
{{Use dmy dates|date=November 2019}}
{{Infobox company
| name = Abbott Laboratories
| logo = Abbott Laboratories 2025 logo.svg
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NYSE|ABT}}|[[S&P 100]] component|[[S&P 500]] component}}
| industry = {{ubl|[[Healthcare industry|Health care]]|[[Medical devices]]|[[Pharmaceutical industry|Pharmaceutical]]}}
| founded = {{Start date and age|df=yes|1888}} (as Abbott Alkaloidal Company) in [[Ravenswood, Chicago]]
| founder = Wallace Calvin Abbott 
| hq_location = Abbott Park, Illinois, U.S.
| area_served = Worldwide
| key_people = {{ubl|class=nowrap|[[Robert B. Ford]]|([[chairman]] & [[Chief Executive Officer|CEO]])<ref>{{cite news |url=https://www.forbes.com/sites/brucejapsen/2018/10/18/after-20-years-abbott-ceo-miles-white-has-his-successor-in-mind|title=After 20 Years, Abbott Labs CEO Miles White Has Successor in Mind |website=Forbes |last1=Japsen |first1=Bruce|access-date=10 September 2019|archive-date=2 February 2023 |archive-url=https://web.archive.org/web/20230202015718/https://www.forbes.com/sites/brucejapsen/2018/10/18/after-20-years-abbott-ceo-miles-white-has-his-successor-in-mind/|url-status=live}}</ref>|Robert Funck|([[Vice president#In business|EVP]] & [[Chief financial officer|CFO]])}}
| products = {{ubl|[[Medication|Pharmaceutical drugs]] |[[Generic drug]]s |[[Medical device]]s |Diagnostic [[assay]]s |[[Dietary supplements]] |[[Nutrition]]als }}
| revenue = {{increase}} {{US$|41.9&nbsp;billion|link=yes}} (2024)
| operating_income = {{increase}} US$6.82&nbsp;billion (2024)
| net_income = {{increase}} US$13.4&nbsp;billion (2024)
| assets = {{increase}} US$81.4&nbsp;billion (2024)
| equity = {{increase}} US$47.9&nbsp;billion (2024)
| num_employees = {{circa|114,000}} (2024)
| website = {{URL|abbott.com}}
| footnotes = <ref name=10K>{{cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1800/000162828025007110/abt-20241231.htm |title=US SEC: Form 10-K Abbott Laboratories |publisher=[[U.S. Securities and Exchange Commission]] |date=February 21, 2025}}</ref>
}}
'''Abbott Laboratories''', commonly known as '''Abbott''', is an American multinational medical devices and [[health care]] company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues).<ref name=10K/>

Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide.<ref name=10K/>

Abbott's products include [[Pedialyte]], [[Similac]], [[BinaxNOW]], [[Ensure]], [[Glucerna]], [[ZonePerfect]], [[FreeStyle Libre]], [[i-STAT]] and [[MitraClip]].<ref name=10K/>

The company is ranked 107th on the [[Fortune 500]]<ref>{{cite web | url=https://fortune.com/company/abbott-laboratories/ | title=Abbott Laboratories | work=[[Fortune (magazine)|Fortune]] | url-access=subscription}}</ref> and 144th on the [[Forbes Global 2000]].<ref>{{Cite web | url=https://www.forbes.com/companies/abbott-laboratories/ | title=Abbott Laboratories | work=[[Forbes]]}}</ref>

==History==
===Foundation and early history===
{{anchor|Wallace Abbott}}
[[File:Dr. Wallace C. Abbott.jpg|thumb|right|Dr. Wallace C. Abbott]]
{{See also|Dr. Wallace C. Abbott House}}
In 1888 at the age of 30, Wallace Abbott (1857–1921), an 1885 graduate of the [[University of Michigan]], founded the '''Abbott Alkaloidal Company''' in [[Ravenswood, Chicago]]. At the time, he was a practising physician and owned a drug store. His innovation was formulating the active part of [[alkaloid]] [[Herbalism|medicinal plants]]—[[morphine]], [[quinine]], [[strychnine]] and [[codeine]]—as tiny "dosimetric granules", producing more consistent and effective dosages for patients than the liquid preparations previously used, which deteriorated over time.<ref>{{cite web |url=http://www.fundinguniverse.com/company-histories/Abbott-Laboratories-Company-History.html |title=Abbott Laboratories Company History |publisher=Funding Universe |access-date=17 April 2013 |archive-date=2 June 2012 |archive-url=https://web.archive.org/web/20120602214830/http://www.fundinguniverse.com/company-histories/Abbott-Laboratories-Company-History.html |url-status=live }}</ref> In 1922, the company moved from Ravenswood to [[North Chicago, Illinois]].{{citation needed|date=December 2022}}

===International expansion===
Abbott's first international affiliate was in London in 1907; the company later added an affiliate in Montreal, Canada.{{citation needed|date=June 2020}} Abbott India Ltd was originally incorporated on August 22, 1944, as Boots Pure Drug Company (India) Ltd. The company name was changed to The Boots Company (India) Ltd on November 1, 1971, and to Boots Pharmaceuticals Ltd on January 1, 1991. On October 31, 1995, the name was changed to Knoll Pharmaceuticals Ltd and on July 1, 2002, to their present name Abbott India Ltd. Abbott started operations in Pakistan as a marketing affiliate in 1948; the company has steadily expanded to comprise a work force of over 1500 employees. Currently, two manufacturing facilities at Landhi and Korangi in [[Karachi]] continue to produce pharmaceutical products.<ref>{{Cite web |url=https://www.pk.abbott/homepage.html|title=Abbott in Pakistan &#124; Abbott |website=www.pk.abbott|access-date=5 July 2023|archive-date=18 June 2021|archive-url=https://web.archive.org/web/20210618065938/https://www.pk.abbott/homepage.html |url-status=live}}</ref> In 1962, Abbott entered into a joint venture with Dainippon Pharmaceutical Co., Ltd., of Osaka, Japan, to manufacture radio-pharmaceuticals.{{citation needed|date=June 2020}} In 1964, it merged with Ross Laboratories, making Ross a wholly owned subsidiary of Abbott, and Richard Ross gained a seat on Abbott's board of directors until his retirement in 1983.<ref>{{cite web |url=https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|title=RICHARD MOORE ROSS, 77, ABBOTT LABS EXECUTIVE |website=[[Chicago Tribune]] |date=11 December 1993 |access-date=2 June 2019 |archive-date=30 September 2022 |archive-url=https://web.archive.org/web/20220930075607/https://www.chicagotribune.com/news/ct-xpm-1993-12-11-9312110107-story.html|url-status=live}}</ref> The acquisition of Ross brought Similac under the Abbott umbrella. In the years following the acquisition, Pedialyte and Ensure were introduced as nutritional products by Ross Laboratories while under Abbott's leadership.<ref>{{Cite web |url=https://ohiohistorycentral.org/w/Ross_Laboratories |title=Ross Laboratories - Ohio History Central |website=ohiohistorycentral.org |access-date=2020-04-02 |archive-date=30 September 2022 |archive-url=https://web.archive.org/web/20220930000742/https://ohiohistorycentral.org/w/Ross_Laboratories |url-status=live }}</ref><ref>{{Cite web |url=https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |title=Abbott Labs plans $62 million investment in Columbus |last=Rose |first=Marla Matzer |website=The Columbus Dispatch |language=en |access-date=2020-04-02 |archive-date=20 August 2020 |archive-url=https://web.archive.org/web/20200820173356/https://www.dispatch.com/business/20190222/abbott-labs-plans-62-million-investment-in-columbus |url-status=dead }}</ref><ref>{{Cite web |url=https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |title=Welcome Sherri Blanchard, M.D., to Douglas Primary Care – Casper, WY Oil City News |date=2020-01-10 |website=Oil City News |language=en-US |access-date=2020-04-02 |archive-date=29 November 2022 |archive-url=https://web.archive.org/web/20221129201413/https://oilcity.news/general/2020/01/10/welcome-sherri-blanchard-m-d-to-douglas-primary-care/ |url-status=live }}</ref>

In 1965, Abbott's expansion in Europe continued with offices in Italy and France.{{citation needed|date=December 2022}}

According to Harvard professor [[Lester Grinspoon]] and Peter Hedblom, "In 1966 Abbott Laboratories sold the equivalent of two million doses of [[methamphetamine]] in powder form to a Long Island criminal dealer".<ref name="grinspoon23">{{cite book |last1=Grinspoon |first1=Lester |last2=Hedblom |first2=Peter |title=The Speed Culture: Amphetamine Use and Abuse in America |date=1975 |publisher=Harvard University Press |location=Cambridge, Massachusetts |isbn=9780674831926 |oclc=1362148 | page=[https://archive.org/details/speedcultureamph0000grin_n3i0/page/23 23] |url=https://archive.org/details/speedcultureamph0000grin_n3i0 |url-access=registration |quote=strasenburgh prescription.}}</ref>

In 1985, Abbott partnered with [[Taisho Pharmaceutical]] for the international rights to [[clarithromycin]], a second-generation [[macrolide]] [[antibiotic]], and gained FDA approval for the drug under the brand name Biaxin in October 1991. [[Generic drug]] versions were approved in Europe in 2004 and in the US in mid-2005,<ref name="pmid25165548">{{cite journal | vauthors=Vieweg WV, Hancox JC, Hasnain M, Koneru JN, Gysel M, Baranchuk A | title=Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports | journal=Therapeutic Advances in Infectious Disease | volume=1 | issue=4 | pages=121–138 | date=August 2013 | pmid=25165548 | pmc=4040724 | doi=10.1177/2049936113497203 }}</ref> and has been added to the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO-2019">{{cite book | title=World Health Organization model list of essential medicines: 21st list 2019 | year=2019 | hdl=10665/325771 | publisher=[[World Health Organization]] | location=[[Geneva]] | id=WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO | hdl-access=free }}</ref>

===2001–2010===
In 2001, the company acquired Knoll, the pharmaceutical division of [[BASF]], for $6.9&nbsp;billion.<ref>{{Cite news |url=https://www.chicagotribune.com/2001/03/03/abbott-closes-early-on-knoll-acquisition/ |title=Abbott Closes Early On Knoll Acquisition |date=March 3, 2001 |work=Chicago Tribune}}</ref> In 2002, it divested the [[Selsun Blue]] brand to [[Chattem]].<ref>{{Cite news |url=https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |title=Company News; Chattem Buys Selsun Blue Shampoo Brand From Abbott |date=March 6, 2002 |work=The New York Times |agency=Reuters |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2002/03/06/business/company-news-chattem-buys-selsun-blue-shampoo-brand-from-abbott.html |url-status=live }}</ref> Later in 2002, it sold [[Clear Eyes]] and Murine brands to [[Prestige Brands]].<ref>{{Cite web |last=Smith |first=Scott S. |date=January 11, 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref>

In 2004, Abbott completed the [[corporate spin-off]] of [[Hospira]], its hospital products division.<ref>{{Cite web |url=https://www.bizjournals.com/austin/stories/2004/01/26/story3.html |title=Abbott Labs to spin off unit |last=Higginbotham |first=Stacey | work=[[American City Business Journals]] |date=January 25, 2004 |archive-date=14 January 2016 |archive-url=https://web.archive.org/web/20160114210453/http://www.bizjournals.com/austin/stories/2004/01/26/story3.html |url-status=live }}</ref> It was acquired by [[Pfizer]] in 2015.<ref>{{Cite web |url=https://marketrealist.com/2016/09/pfizers-hospira-deal-catching-up-a-year-later/ |title=Pfizer's Hospira Deal: Catching Up a Year Later |last=Dabney |first=Jillian |website=Market Realist |date=2016-09-09 |archive-date=28 September 2022 |archive-url=https://web.archive.org/web/20220928145919/https://marketrealist.com/2016/09/pfizers-hospira-deal-catching-up-a-year-later/ |url-status=live }}</ref>

In 2004, it acquired TheraSense, a [[diabetes]]-care company, which it merged with its MediSense division to become Abbott Diabetes Care.<ref>{{Cite news |last=Sandred |first=Jan |date=January 14, 2004 |title=$1 billion medical deal / Abbott Labs to buy Therasense, maker of glucose monitors |url=https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |work=SFGATE |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.sfgate.com/bayarea/article/1-billion-medical-deal-abbott-labs-to-buy-2812649.php |url-status=live }}</ref>{{additional citation needed|date=June 2020}} In 2006, Abbott assisted [[Boston Scientific]] in its purchase of [[Guidant]] Corporation purchasing the vascular device division of Guidant.<ref>{{Cite news |last1=Feder |first1=Barnaby |last2=Sorkin |first2=Andrew Ross |date=January 18, 2006 |title=Boston Scientific, With Abbott's Help, Raises Bid for Guidant |url=https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.nytimes.com/2006/01/18/business/boston-scientific-with-abbotts-help-raises-bid-for-guidant.html |url-status=live }}</ref><ref>{{Cite news |last=Feder |first=Barnaby |date=September 27, 2006 |title=Johnson & Johnson Sues Boston Scientific, Guidant and Abbott Laboratories Over Deal |url=https://www.nytimes.com/2006/09/27/business/27device.html |work=The New York Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070500/https://www.nytimes.com/2006/09/27/business/27device.html |url-status=live }}</ref>

In 2007, Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash.<ref>{{cite news |last=Smith |first=Scott S. |date=11 January 2018 |title=Miles White's Bold Moves Made Abbott Laboratories A Global Force |url=https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |work=Investor's Business Daily |access-date=25 December 2018 |archive-date=20 November 2021 |archive-url=https://web.archive.org/web/20211120121814/https://www.investors.com/news/management/leaders-and-success/miles-whites-bold-moves-made-abbott-laboratories-a-global-force/ |url-status=live }}</ref> At the time of acquisition Kos marketed Niaspan (extended release [[niacin (substance)|niacin]]), and Advicor ([[niacin/lovastatin]]).

In 2007, the company was to sell two diagnostics divisions to [[General Electric]], but the parties did not agree on the terms of the acquisition.<ref>{{cite news | last1=Layne | first1=Rachel | last2=Lopatto | first2=Elizabeth | url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | title=GE, Abbott End $8.13 Billion Diagnostic Sale Deal (Update2) | agency=Bloomberg News | date=11 July 2007 | access-date=5 March 2017 | archive-date=24 September 2015 | archive-url=https://web.archive.org/web/20150924153211/http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aLKvFFqD3DQw | url-status=live }}</ref>

On 8 September 2007, the company sold the UK manufacturing plant at [[Queenborough]] to UK manufacturer Aesica Pharmaceuticals.<ref>{{Cite web |url=https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |title=Aesica Containment Facility |date=November 7, 2013 |website=Pharmaceutical Technology |access-date=10 March 2024 |archive-date=7 June 2023 |archive-url=https://web.archive.org/web/20230607023207/https://www.pharmaceutical-technology.com/projects/aesicasnewcontainmen/ |url-status=live }}</ref><ref>{{Cite news |last=Tighe |first=Chris |date=July 8, 2007 |title=Aesica seizes some bargain buys |url=https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |work=Financial Times |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.ft.com/content/9b5346fe-2d66-11dc-939b-0000779fd2ac |url-status=live }}</ref>

Abbott's Ross Products was renamed Abbott Nutrition in 2007.<ref>{{Cite web |last=Wilson |first=Paul |title=End of an era: Abbott retires Ross Products name |url=https://www.dispatch.com/story/news/2007/11/08/end-era-abbott-retires-ross/24057637007/ |access-date=2020-04-02 |website=The Columbus Dispatch |language=en}}</ref>

In 2009, Abbott acquired [[Advanced Medical Optics]] of [[Santa Ana, California]], selling it to [[Johnson & Johnson]] in 2017.<ref>{{cite web|url=https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|title=Johnson & Johnson completes $4.3B acquisition of Abbott Medical Optics in Santa Ana|website=Orange County Register|date=28 February 2017|access-date=22 November 2019|archive-date=2 December 2022|archive-url=https://web.archive.org/web/20221202033619/https://www.ocregister.com/2017/02/28/johnson-johnson-completes-43b-acquisition-of-abbott-medical-optics-in-santa-ana/|url-status=live}}</ref> In 2009, Abbott opened a satellite research and development facility at [[Research Park, University of Illinois at Urbana-Champaign]].<ref>{{cite web|url=https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|title=Abbott Labs leasing space in UI research park|website=The News Gazette|date=2 May 2009|access-date=22 November 2019|archive-date=20 November 2022|archive-url=https://web.archive.org/web/20221120024440/https://www.news-gazette.com/news/abbott-labs-leasing-space-in-ui-research-park/article_daf381df-df4d-5516-90c8-9ef89ed56d36.html|url-status=live}}</ref>

In February 2010, Abbott acquired the pharmaceuticals unit of [[Solvay S.A.]] for [[US$]]6.2 billion ([[€]]4.5 billion),<ref>{{cite press release | url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-solvay-pharmaceuticals-84432642.html | title=Abbott Completes Acquisition of Solvay Pharmaceuticals | publisher=[[PR Newswire]] | date=February 26, 2010}}</ref> gaining many additional pharmaceutical products and an increased presence in emerging markets.<ref name="Abbott-Feb-2010-8-K">{{cite web |url=http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |title=Abbott Laboratories Feb 2010 Current Report, Form 8-K, Filing Date Feb 16, 2010 |publisher=secdatabase.com |access-date=27 December 2012 |archive-date=23 May 2013 |archive-url=https://web.archive.org/web/20130523222642/http://pdf.secdatabase.com/205/0001104659-10-007120.pdf |url-status=live }}</ref>

In 2010, the company acquired [[Hollywood, Florida]]-based [[laboratory information management system]] company [[STARLIMS]] for $123 million, $14 per share.<ref>{{Cite news |url=https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |title=Abbott sets deal to buy Starlims |date=December 15, 2009 |work=Chicago Tribune |access-date=10 March 2024 |archive-date=10 March 2024 |archive-url=https://web.archive.org/web/20240310070459/https://www.chicagotribune.com/2009/12/15/abbott-sets-deal-to-buy-starlims/ |url-status=live }}</ref><ref>{{Cite press release |url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-starlims-technologies-88846137.html |title=Abbott Completes Acquisition of STARLIMS Technologies |date=March 22, 2010 |publisher=PR Newswire}}</ref> That year Abbott said it would buy [[Piramal Group]] of India's large generic drugs unit for $3.72 billion.<ref>{{cite news |url=https://www.wsj.com/articles/SB10001424052748704852004575257614197847830|title=Abbott Labs to Buy Indian Business | first1=Peter | last1=Loftus | first2=Rumman | last2=Ahmed |work=[[The Wall Street Journal]] |access-date=26 September 2019 |archive-date=5 August 2023|archive-url=https://web.archive.org/web/20230805093503/http://www.wsj.com/articles/SB10001424052748704852004575257614197847830|url-status=live}}</ref>


===2013–present===
Effective January 1, 2013, the company completed the [[corporate spin-off]] of [[AbbVie]].<ref>{{cite news |last=Armstrong |first=Drew |title=AbbVie Rises on First Day of Trading After Abbott Spinoff |url=https://www.bloomberg.com/news/articles/2013-01-02/abbvie-rises-on-first-day-of-trading-after-abbott-spinoff |work=[[Bloomberg News]] |date=2 January 2013 |archive-date=30 March 2022 |archive-url=https://web.archive.org/web/20220330020520/https://www.bloomberg.com/news/articles/2013-01-02/abbvie-rises-on-first-day-of-trading-after-abbott-spinoff|url-status=live}}</ref><ref>{{cite press release |url=https://www.prnewswire.com/news-releases/abbott-completes-separation-of-research-based-pharmaceuticals-business-185406542.html |title=Abbott Completes Separation of Research-Based Pharmaceuticals Business |publisher=[[PR Newswire]] |date=January 2, 2013}}</ref><ref>{{cite news |url=https://www.chicagotribune.com/business/ct-xpm-2012-12-30-ct-biz-1230-bf-abbott-spin-20121230-story.html |title=More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie |work=[[Chicago Tribune]] |date=December 30, 2012 |url-access=limited |archive-date=3 July 2021 |archive-url=https://web.archive.org/web/20210703062233/https://www.chicagotribune.com/business/ct-xpm-2012-12-30-ct-biz-1230-bf-abbott-spin-20121230-story.html |url-status=live }}</ref><ref name=nyt>{{cite news |url=https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two|title=Abbott Labs to Split into 2 Companies |first1=Michael |last1=de La Merced | first2=Bruce |last2=Japsen |newspaper=[[The New York Times]] |date=19 October 2011 |archive-date=17 June 2022|archive-url=https://web.archive.org/web/20220617065658/https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two/ |url-status=live}}</ref><ref>{{cite news |last1=Rockoff |first1=Jonathan D. |title=Abbott to Split into Two Companies |url=https://www.wsj.com/articles/SB10001424052970204485304576640740820288766 |work=[[The Wall Street Journal]] |date=20 October 2011 | url-access=subscription |archive-date=12 December 2022 |archive-url=https://web.archive.org/web/20221212040813/http://www.wsj.com/articles/SB10001424052970204485304576640740820288766 |url-status=live}}</ref> Abbott Nutrition, whose products include Similac, Pedialyte, Glucerna, and Ensure, also retained the Abbott name.<ref name=nyt /> In preparation for the reorganization, Abbott cut 550 staff members.<ref name=frost2012>{{Cite news | url=https://www.cnbc.com/2012/10/17/abbott-labs-3q-net-income-rises-lays-off-550.html | title=Abbott Labs 3Q net income rises; lays off 550 | work=[[CNBC]] | date=October 17, 2012}}</ref> 

In May 2014, it was announced that Abbott would acquire the [[holding company]] Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, [[CFR Pharmaceuticals]], which the company said would more than double its branded generic drug portfolio.<ref>{{cite web |url=https://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html |title=Abbott to acquire CFR Pharmaceuticals |website=[[Bloomberg News]] |date=16 May 2014 |access-date=16 May 2014 |archive-date=19 December 2014 |archive-url=https://web.archive.org/web/20141219070557/http://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html |url-status=live}}</ref><ref>{{Cite news |title=Abbott Grows Branded Generics with $3.3B CFR Acquisition | work=[[Genetic Engineering & Biotechnology News]] |date=15 June 2014}}</ref>

In December 2014, the company acquired Russian pharmaceutical manufacturer Veropharm ([[Voronezh]]) in a deal worth $410 million, which included three manufacturing facilities.<ref>{{cite web | url=https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/ |title=Abbott Acquires Veropharm To Expand Presence in Russia|website=Forbes|access-date=17 October 2019 |archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820173042/https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/|url-status=live}}</ref> Abbott, which already employed 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.<ref>{{cite web |url=https://www.reuters.com/finance/stocks/ABT/key-developments|archive-url=https://web.archive.org/web/20110825120828/http://www.reuters.com/finance/stocks/ABT/key-developments |url-status=dead |archive-date=2011-08-25 |title=Abbott Laboratories (ABT) Key Developments |work=Reuters.com}}</ref>

In September 2015, the company acquired Tendyne Holdings, a private medical device company focused on developing minimally invasive mitral valve replacement therapies, for $250 million.<ref name=autogenerated1>{{Cite web |url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-tendyne-holdings-inc-300136563.html |title=Abbott Completes Acquisition of Tendyne Holdings, Inc. | publisher=[[PR Newswire]] | date=September 1, 2015}}</ref><ref>{{Cite news | url=https://www.jonesday.com/en/practices/experience/2015/09/abbott-acquires-tendyne-holdings | title=Abbott acquires Tendyne Holdings | work=[[Jones Day]] | date=September 2015}}</ref>

In September 2017, the FDA approved Abbott's FreeStyle Libre glucose monitoring system, which reads glucose levels through a self-applied sensor without finger pricks.<ref>{{cite web |url=https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/ |title=FDA approves Abbott's Freestyle Libre glucose monitoring system |website=Medical Device Network |date=29 September 2017 |archive-date=17 October 2019 |archive-url=https://web.archive.org/web/20191017194312/https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/ |url-status=live}}</ref>

In October 2017, the company acquired [[Alere]] for $5.8 billion.<ref>{{cite web |url=http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/|title=Abbott to Acquire Alere for $5.8B |work=[[Genetic Engineering & Biotechnology News]] |date=February 2016 |access-date=1 February 2016|archive-date=2 February 2016 |archive-url=https://web.archive.org/web/20160202113917/http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/ |url-status=live}}</ref><ref>{{cite web |url=https://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share |title=Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest|author=Michelle Cortez |date=1 February 2016 |publisher=Bloomberg L.P. |access-date=5 March 2017|archive-date=11 October 2016 |archive-url=https://web.archive.org/web/20161011185155/http://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share|url-status=live}}</ref> In January 2017, Abbott announced it would acquire [[St. Jude Medical]] for $25 billion in stock.<ref>{{cite web |url=https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion |title=Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion |author=Michelle Cortez |date=28 April 2016 |publisher=Bloomberg L.P. |access-date=5 March 2017|archive-date=7 March 2020|archive-url=https://web.archive.org/web/20200307111910/https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion|url-status=live}}</ref><ref>{{cite web | url=https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense | title=Abbott-St. Jude Combination: Why It Makes Sense |date=28 April 2016 |publisher=Bloomberg L.P. | access-date=5 March 2017 |archive-date=15 April 2017 |archive-url=https://web.archive.org/web/20170415200817/https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense |url-status=live}}</ref><ref>{{cite web |url=http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254 | title=Abbott to Gain from Alere's Takeover Due for Oct 3 Closure |work=GEN |access-date=5 October 2017 | archive-date=5 October 2017 |archive-url=https://web.archive.org/web/20171005141211/http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254 |url-status=live}}</ref> With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which at one point was the largest mail-order diabetic supplier.<ref>{{Cite press release | url=https://www.justice.gov/archives/opa/pr/mail-order-diabetic-testing-supplier-and-parent-company-agree-pay-160-million-resolve-alleged | title=Mail-Order Diabetic Testing Supplier and Parent Company Agree to Pay $160 Million to Resolve Alleged False Claims to Medicare | publisher=[[United States Department of Justice]] | date=August 2, 2021}}</ref> Arriva Medical closed facilities in December 2017.<ref>{{cite web |url=http://www.hmenews.com/article/embattled-arriva-medical-closes |title=Embattled Arriva Medical closes |work=GEN |access-date=6 December 2017 |archive-date=6 December 2017 |archive-url=https://web.archive.org/web/20171206221738/http://www.hmenews.com/article/embattled-arriva-medical-closes |url-status=live}}</ref>

As of August 2018, the company was among the top five companies for branded generic drugs in Russia.<ref>{{cite news |title=Factbox: U.S. companies with exposure to Russia |url=https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |work=Reuters |date=9 August 2018 |access-date=29 January 2019 |archive-date=1 December 2020 |archive-url=https://web.archive.org/web/20201201061738/https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |url-status=live }}</ref>

[[File:ID Now testing (51038387158).jpg|thumb|Nucleic acid testing for COVID-19 conducted using an Abbott Laboratories ID Now device]]
In November 2018, Abbott received United States FDA clearance for FreeStyle LibreLink, a glucose reader [[smartphone app]].<ref>{{cite web|url=https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|title=With new FDA clearance, Abbott Freestyle Libre users can ditch handheld readers for an app |website=Mobi Health News |date=November 2018 |access-date=17 October 2019 |archive-date=20 February 2020 |archive-url=https://web.archive.org/web/20200220045000/https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|url-status=live}}</ref>

In January 2019, the company acquired Cephea Valve Technologies, which is developing a less-invasive replacement heart valve for people with mitral valve disease.<ref>{{cite web |url=https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/|title=Abbott To Acquire Cephea Valve Technologies, Inc. |website=BioSpace|access-date=2 June 2019|archive-date=20 August 2020 |archive-url=https://web.archive.org/web/20200820173325/https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/ |url-status=live}}</ref>

In January 2020, the Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve Replacement Technology; with CE Mark for the device, it is possible to implant it in Europe outside of a clinical setting.<ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/abbotts-tendyne-device-receives-worlds-first-ce-mark-for-transcatheter-mitral-valve-implantation-300995780.html | title=Abbott's Tendyne™ Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation | publisher=[[PR Newswire]] | date=January 30, 2020}}</ref>

In March 2020, Abbott received [[emergency use authorization]] (EUA) from the US FDA for a [[SARS-CoV-2]] test during the [[COVID-19 pandemic]].<ref>{{cite web|url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=International Business Times |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020 |url-status=live}}</ref> The tester is small (comparable to a small toaster), and produces results within 13 minutes.<ref>{{Cite web |url=https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|title='A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster|last=Hauck|first=Grace|website=USA Today | language=en-US |access-date=2020-03-30 |archive-date=28 April 2020|archive-url=https://web.archive.org/web/20200428170404/https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|url-status=live}}</ref> Detroit received these tests on April 1, 2020.<ref>{{Cite news | url=https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ | title=The scramble for the rapid coronavirus tests everybody wants |last=Mufson |first=Steven | newspaper=[[The Washington Post]] |language=en |access-date=2020-04-02 |archive-date=10 February 2021 | archive-url=https://web.archive.org/web/20210210022633/https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ |url-status=live }}</ref><ref>{{Cite web | url=https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |title=Detroit to be first to deploy Abbott Labs' 5-minute COVID-19 test, mayor says | last=Burns |first=Matt |website=TechCrunch |date=2 April 2020 |language=en-US |access-date=2020-04-02 | archive-date=17 July 2024 |archive-url=https://web.archive.org/web/20240717135224/https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |url-status=live }}</ref> Also in March, the firm received EUA for a molecular COVID-19 test that runs on its m2000 RealTime lab-based platform.<ref>{{cite web |title=Abbott receives FDA emergency use authorization for coronavirus test | last=Newmaker |first=Chris |url=https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/ |website=massdevice.com |access-date=13 April 2021|date=19 March 2020 |archive-date=13 April 2021 |archive-url=https://web.archive.org/web/20210413192459/https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/|url-status=live}}</ref> In April 2020, itt received EUA from the FDA for its third COVID-19 test, an antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's ARCHITECT laboratory instruments.<ref name="medtechcorona">{{cite web | title=Abbott enters coronavirus antibody testing fray |last=Rachal |first=Maria | url=https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/ | website=medtechdive.com |date=15 April 2020 |access-date=13 April 2021 |archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413192459/https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/|url-status=live}}</ref> In May 2020, it received EUA from the FDA for another lab-based COVID-19 antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's Alinity i system.<ref name="medtechcorona" /><ref>{{cite web|title=Latest Abbott coronavirus antibody test receives FDA emergency use OK | last=Slabodkin | first=Greg | url=https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/ |website=medtechdive.com|date=11 May 2020|access-date=13 April 2021|archive-date=13 April 2021 |archive-url=https://web.archive.org/web/20210413201434/https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/|url-status=live}}</ref> Also in May, it received EUA from the FDA for a molecular COVID-19 test for use on the company's Alinity molecular laboratory instrument.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Pepper | first2=Gregory |last3=Shrestha |first3=Lasata |last4=LaTurner |first4=Katrina |last5=Yae Kim |first5=Da | last6=Huang |first6=Meei-Li |last7=Jerome |first7=Keith R. |last8=Greninger |first8=Alexander L.|author8-link=Alexander L. Greninger |date=July 2021 |title=Performance characteristics of the Abbott Alinity m SARS-CoV-2 assay |journal=Journal of Clinical Virology |volume=140 |article-number=104869 | doi=10.1016/j.jcv.2021.104869 |issn=1386-6532 |pmc=8118701 |pmid=34023572}}</ref><ref>{{cite web | title=Two Abbott COVID-19 tests receive EUA | last=Boyle |first=Annette |url=https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua |website=bioworld.com |date=12 May 2020 |access-date=13 April 2021 |archive-date=13 April 2021 |archive-url=https://web.archive.org/web/20210413201443/https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua |url-status=live}}</ref>

In August 2020, Abbott received EUA from the FDA for its credit-card-sized $5, 15-minute, portable COVID-19 antigen test, BinaxNOW, compatible with the NAVICA mobile app.<ref>{{cite web|title=Abbott wins EUA for COVID-19 test that runs off a card |last=Newmarker |first=Chris|url=https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/|website=massdevice.com|date=27 August 2020|access-date=13 April 2021 |archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201432/https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/ |url-status=live}}</ref><ref>{{cite news|title=This $5 rapid test is a potential game-changer in COVID-19 testing|url=https://abc7.com/binaxnow-binax-now-coronavirus-test-rapid/6391998/ |website=abc7.com|date=27 August 2020}}</ref>

In October 2020, Abbott received EUA from the FDA for its lab-based COVID-19 IgM antibody blood test.<ref>{{cite web |title=Abbott wins FDA EUA for COVID-19 IgM antibody test |last=Whooley |first=Sean | url=https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/ | website=massdevice.com |date=13 October 2020|access-date=14 April 2021|archive-date=14 April 2021 | archive-url=https://web.archive.org/web/20210414183002/https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/ |url-status=live}}</ref> In December 2020, its rapid (20') antigen BinaxNOW COVID-19 test received EUA from the FDA for home use.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Huang |first2=Meei-Li |last3=Mills |first3=Margaret G. |last4=Jerome |first4=Keith R. |author5-link=Alexander L. Greninger |last5=Greninger |first5=Alexander L. |date=2021-02-18 |editor-last=Loeffelholz |editor-first=Michael J. |title=Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card |journal=Journal of Clinical Microbiology |language=en |volume=59 |issue=3 |pages=e02880–20 |doi=10.1128/JCM.02880-20 |issn=0095-1137 |pmc=8106729 |pmid=33310764}}</ref><ref>{{cite web|title=Abbott Labs' at-home, $25 rapid COVID-19 test gets EUA from FDA |last=Kilgore |first=Tomi |url=https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16 | work=[[MarketWatch]] |date=16 December 2020 |access-date=14 April 2021 |archive-date=14 April 2021 |archive-url=https://web.archive.org/web/20210414183002/https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16|url-status=live}}</ref> ''Forbes'' reported in January 2021 that the firm had delivered more than 400 million COVID-19 tests, 300 million in the fourth quarter of 2020.<ref>{{cite web |title=Abbott Profits Rise As Covid-19 Diagnostic Sales Eclipse 400 Million Tests |last=Japsen |first=Bruce |url=https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|website=Forbes|date=27 January 2021 |access-date=14 April 2021 |archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|url-status=live}}</ref>

In September 2021, Abbott acquired Walk Vascular, LLC.<ref>{{Cite web |url=https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|title=Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC |date=2 September 2021 |access-date=3 September 2021|archive-date=3 September 2021 |archive-url=https://web.archive.org/web/20210903201150/https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|url-status=live}}</ref>

In January 2022, Abbott introduced Lingo, a line of consumer biowearable sensors that collects a range of biological readings to optimize exercise and nutrition regimens.<ref>{{cite news |url=https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech | first=Andrea | last=Park |title=Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech | work=[[FierceBiotech]] | publisher=[[Questex]] |date=January 6, 2022 |archive-date=23 January 2023 |archive-url=https://web.archive.org/web/20230123191646/https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech|url-status=live}}</ref>

Following the [[2022 Russian invasion of Ukraine]], Abbott Laboratories continued its business operations in Russia while suspending non-essential activities such as new investments and advertising.<ref>{{Cite web |last=Varney |first=Sarah |date=2022-03-10 |title=Which Companies Aren't Exiting Russia? Big Pharma |url=https://kffhealthnews.org/news/article/big-pharma-reaction-russia-ukraine-war/ |access-date=2025-02-20 |website=KFF Health News |language=en-US}}</ref> Research from [[Yale School of Management]] evaluating corporate responses to the invasion placed Abbott in the "Buying Time" category with a "Grade D" rating, indicating that it postponed future investments and marketing while continuing substantive business in Russia.<ref>{{Cite web |title=Over 1,000 Companies Have Curtailed Operations in Russia—But Some Remain {{!}} Yale School of Management |url=https://som.yale.edu/story/2022/over-1000-companies-have-curtailed-operations-russia-some-remain |access-date=2025-02-20 |website=som.yale.edu |language=en}}</ref>

In May 2022, Abbott received 510(k) clearance from the FDA for FreeStyle Libre 3, the latest version of its continuous glucose monitor.<ref>{{cite news |url=https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/ |author=Nick Paul Taylor |date=May 31, 2022|title=Abbott's Libre 3 glucose monitor gets FDA clearance as CGM market intensifies |work=MedTechDive|access-date=29 December 2022|archive-date=29 December 2022 |archive-url=https://web.archive.org/web/20221229030224/https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/|url-status=live}}</ref>

In August 2022, Abbott received FDA approval for Proclaim Plus, a multi-use spinal cord stimulation system designed to target chronic pain. The Proclaim Plus system is capable of treating six independent pain sites and has a recharge-free battery life of up to 10 years.<ref>{{cite news |url=https://www.fiercebiotech.com/medtech/abbott-proclaims-fda-approval-neurostimulator-treat-pain-six-areas-once | first=Andrea | last=Park |title=Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once | work=[[FierceBiotech]] | publisher=[[Questex]] | date=August 23, 2022}}</ref>

In October 2022, Abbott received EUA from the FDA for its real-time [[Polymerase chain reaction|PCR]] test Alinity m MPXV; this marks the first FDA emergency authorization for commercial monkeypox testing.<ref>{{cite news |url=https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/ |author=Nick Paul Taylor |date=October 10, 2022 |title=Abbott lands FDA emergency authorization for first commercial monkeypox test |work=MedTechDive |access-date=29 December 2022 |archive-date=29 December 2022|archive-url=https://web.archive.org/web/20221229024014/https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/|url-status=live}}</ref>

In April 2023, the company acquired Cardiovascular Systems, developer of an atherectomy system, which is used in treating peripheral and coronary artery disease, for $851 million.<ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-cardiovascular-systems-inc-301810183.html | title=Abbott Completes Acquisition of Cardiovascular Systems, Inc. | publisher=[[PR Newswire]] | date=April 27, 2023}}</ref>

On July 5, 2023, Abbott received approval from the FDA for its leadless pacemaker system Aveir DR.<ref name="aveirdr" /> 

In September 2023, the company acquired Bigfoot Biomedical, a developer of smart insulin management systems for people with diabetes.<ref>{{Cite press release | url=https://www.prnewswire.com/news-releases/abbott-completes-acquisition-of-bigfoot-biomedical-301936187.html | title=Abbott Completes Acquisition of Bigfoot Biomedical | publisher=[[PR Newswire]] | date=September 22, 2023}}</ref><ref>{{cite web | url=https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/ | title=Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes | date=5 September 2023 | access-date=7 September 2023 | archive-date=7 September 2023 | archive-url=https://web.archive.org/web/20230907113323/https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/?s=79 | url-status=live }}</ref>

===Acquisition history===
{{hidden begin|border=1px #aaa solid|title=Abbott Laboratories Acquisitions|ta1=center}}
{{Tree list}}
* '''Abbott Laboratories''' <small>(Est. 1885, Abbott Alkaloidal Company)</small>
** Ross Laboratories <small>(Acq 1964)</small>
** SmithKline Beecham <small>(Acq 1982, later sold)</small>
** [[BASF|Knoll]] <small>(Acq 2001)</small>
** [[Selsun Blue]] <small>(Sold to [[Chattem]] 2002)</small>
** Murine <small>(Sold to [[Prestige Brands]] 2002)</small>
** Clear Eyes <small>(Sold to [[Prestige Brands]] 2002)</small>
** i-STAT <small>(Acq 2004)</small>
** TheraSense <small>(Acq 2004)</small>
** [[Guidant|Guidant (vascular device division)]] <small>(Acq 2006)</small>
*** IntraLase Corp <small>(Acq 2007)</small>
** [[Advanced Medical Optics]] <small>(Acq 2009)</small>
** Solvay Pharmaceuticals <small>(Acq 2010)</small>
** [[STARLIMS]] <small>(Acq 2010)</small>
*** Lab Data Management Ltd <small>(Acq 2008)</small>
** IDEV Technologies <small>(Acq 2013)</small>
** OptiMedica Corporation <small>(Acq 2013)</small>
** Veropharm <small>(Acq 2014)</small>
** Topera, Inc <small>(Acq 2014)</small>
** Kalo Pharma Internacional S.L. <small>(Acq 2014)</small>
*** [[CFR Pharmaceuticals]]
** [[Tendyne Holdings Inc.]] <small>(Acq 2015)</small>
** [[Alere]] <small>(Acq 2016)</small>
*** Epocal, Inc. <small>(Acq 2013)</small>
*** Arriva Medical <small>(Acq 2012)</small>
** [[St. Jude Medical]] <small>(Est 1976, Acq 2016)</small>
*** Pacesetter, Inc. <small>(Acq 1994)</small>
*** Daig Corporation <small>(Acq 1996)</small>
*** Heart Valve Company <small>(Acq 1996)</small>
*** Biocor Industria <small>(Acq 1996)</small>
*** Ventritex <small>(Acq 1997)</small>
*** [[Tyco International]] (Angio-Seal division) <small>(Acq 1999)</small>
*** Endocardial Solutions <small>(Acq 2005)</small>
*** Advanced Neuromodulation Systems <small>(Acq 2005)</small>
*** MediGuide <small>(Acq 2008)</small>
*** AGA Medical <small>(Acq 2010)</small>
*** LightLab Imaging <small>(Acq 2010)</small>
*** Nanostim Inc <small>(Acq 2013)</small>
*** Endosense <small>(Acq 2013)</small>
*** CardioMEMS Inc. <small>(Acq 2014)</small>
*** Spinal Modulation <small>(Acq 2015)</small>
*** [[Thoratec Corporation]] <small>(Acq 2015)</small>
**** Apica Cardiovascular Limited <small>(Acq 2014)</small>
**** Levitronix (Medical division) <small>(Acq 2011)</small>
**** [[Getinge Group|Getinge Group (Heat pump technology division)]] <small>(Acq 2014)</small>
**** Thermo Cardiosystems <small>(Acq 2010)</small>
** Cephea Valve Technologies, Inc. <small>(Acq 2019)</small>
** Walk Vascular, LLC <small>(Acq 2021)</small>
** Cardiovascular Systems, Inc. <small>(Acq 2023)</small>
** [[Bigfoot Biomedical]] <small>(Acq 2023)</small>{{Tree list/end}}
{{hidden end}}

==Financials==
{| class="wikitable float-left" style="text-align: right;"
!Year
!Revenue<br />in mil. US$
!Net income<br />in mil. US$
!Total assets<br />in mil. US$
!Price per share<br />in US$
!Employees
|-
|2005
|22,338
|3,372
|29,141
|17.37
|
|-
|2006
|22,476
|1,717
|36,178
|17.46
|
|-
|2007
|25,914
|3,606
|39,714
|21.34
|
|-
|2008
|29,528
|4,881
|42,419
|21.89
|
|-
|2009
|30,765
| 5,746
|52,582
|19.51
|
|-
|2010
|35,167
| 4,626
|60,574
|20.75
|
|-
|2011
|21,407
|4,728
|60,277
|21.26
|
|-
|2012
|19,050
|5,963
|67,235
|26.57
|
|-
|2013
|19,657
|2,576
|42,953
|31.90
|69,000
|-
|2014
|20,247
|2,284
|41,207
|37.39
|77,000
|-
|2015
|20,405
| 4,423
|41,247
|43.16
|74,000
|-
|2016
|20,998
|1,400
|52,666
|38.65
|75,000
|-
|2017
|27,390
|477
|76,250
|47.50
|99,000
|-
|2018
|30,578
|2,368
|67,173
|69.50
|103,000
|-
|2019
|31,904
|3,687
|67,887
|86.86
|107,000
|-
|2020
|34,608
|4,495
|72,548
|109.49
|109,000
|-
|2021
|43,075
|7,071
|75,196
|140.74
|113,000
|}

==Operations==
===Organization===
[[File:FreeStyle libre am Oberarm und Auslesegerät-1.JPG|thumb|Abbott's FreeStyle libre]]
Abbott's core businesses focus on diagnostics, medical devices, branded generic medicines and nutritional products, which have been supplemented through acquisitions.<ref name=10K/>

The firm's divisions are:<ref name=10K/>
* Nutrition: [[Infant nutrition|Pediatric nutrition]] (e.g., [[Similac]], Isomil, and Gain), Adult Nutrition (e.g., [[Ensure]] and [[ZonePerfect]]) and special dietary needs (e.g., [[Glucerna]] and [[Juven]])
* Diagnostics: core lab, molecular, point of care, rapid diagnostics and Informatics
* Medical devices: rhythm management, electrophysiology, heart failure, structural heart, neuromodulation, diabetes care
* Established Pharmaceuticals: branded generic drugs sold exclusively in developing markets

===Management===
{{multiple image|align=right|caption_align=center|direction=horizontal|footer_align=center|image1=Miles D. White.jpg|width1=212|caption1=Miles D. White|image2=Robert B Ford.jpg|width2=220|caption2=Robert B. Ford}}
[[Miles D. White]] joined the company in 1984, holding positions including senior vice president of diagnostic operations, executive vice president, executive chairman, and CEO.<ref name=frost2012/> In 1996, Robert B. Ford joined Abbott, holding various positions including executive vice president of the company's medical device business.<ref name=Elfin>{{cite web |url=https://www.medtechdive.com/news/abbott-names-robert-ford-new-ceo-ending-miles-whites-21-year-tenure-in-ma/567222/ |title=Abbott names Robert Ford new CEO, ending Miles White's 21-year tenure in March |website=Medtechdive |author=Dana Elfin|access-date=19 March 2020 |archive-date=14 April 2020 |archive-url=https://web.archive.org/web/20200414065215/https://www.medtechdive.com/news/abbott-names-robert-ford-new-ceo-ending-miles-whites-21-year-tenure-in-ma/567222/ |url-status=live}}</ref>

In November 2019, White announced that he was stepping down as CEO after 21 years.<ref name=Elfin/> In March 2020, Robert B. Ford took over as president and CEO,<ref>{{cite news|title=Abbott CEO Miles White to step down in March |url=https://www.chicagotribune.com/business/ct-biz-abbott-ceo-miles-white-20191113-d7aofcn3lbblxca5ihalvw2bfi-story.html |access-date=April 8, 2020}}</ref> and later chairman.<ref>{{cite news |url=https://www.fiercebiotech.com/medtech/abbott-ceo-ford-elected-chairman-board-as-predecessor-white-retires-after-40-years | first=Andrea | last=Park |title=Abbott elects CEO Ford chairman of the board as predecessor White retires after 40 years |work=[[FierceBiotech]] | publisher=[[Questex]] |date=December 13, 2021 |archive-date=29 December 2022 |archive-url=https://web.archive.org/web/20221229032335/https://www.fiercebiotech.com/medtech/abbott-ceo-ford-elected-chairman-board-as-predecessor-white-retires-after-40-years |url-status=live}}</ref>

==Recognition==
* Named one of its ''Top 50 World's Most Admired Companies'' in 2021 by ''[[Fortune (magazine)|Fortune]]''.<ref>{{Cite web |url=https://fortune.com/company/abbott-laboratories/worlds-most-admired-companies/ |title=World's Most Admired Companies | work=[[Fortune (magazine)|Fortune]] |archive-date=26 October 2021 |archive-url=https://web.archive.org/web/20211026134936/https://fortune.com/company/abbott-laboratories/worlds-most-admired-companies/ |url-status=live}}</ref>

* Named among the [[Blue ribbon]] companies in 2021 by ''[[Fortune (magazine)|Fortune]]''.<ref>{{Cite web |url=https://fortune.com/2020/12/14/blue-ribbon-companies-2021/ |title=Fortune's Blue Ribbon Companies 2021 | work=[[Fortune (magazine)|Fortune]] |archive-date=26 October 2021 | archive-url=https://web.archive.org/web/20211026134934/https://fortune.com/2020/12/14/blue-ribbon-companies-2021/ |url-status=live}}</ref> 

* Named to the ''Change the World'' list in 2020 by ''[[Fortune (magazine)|Fortune]]''.<ref>{{Cite web |url=https://fortune.com/change-the-world/2020/search// |title=Change the World | work=[[Fortune (magazine)|Fortune]] |archive-date=21 September 2021 |archive-url=https://web.archive.org/web/20210921121907/https://fortune.com/change-the-world/2020/search/ |url-status=live}}</ref> 

* Ranked #10 on ''Most Innovative Companies in Sports'' for Libre Sense by ''[[Fast Company]]''.<ref>{{cite news |url=https://www.fastcompany.com/90724478/most-innovative-companies-sports-2022 |author=Jay Woodruff |date=March 8, 2022 |title=The 10 most innovative companies in sports in 2022 |work=Fast Company}}</ref>

* Received an Honorable Mention for the World Changing Ideas Awards by ''[[Fast Company]]'' in 2022.<ref>{{cite news |url=https://www.fastcompany.com/90742519/world-changing-ideas-awards-2022-health-finalists-and-honorable-mentions |date=May 3, 2022 |title=These innovative projects are changing the health industry |work=Fast Company |access-date=13 February 2023 |archive-date=13 February 2023|archive-url=https://web.archive.org/web/20230213200134/https://www.fastcompany.com/90742519/world-changing-ideas-awards-2022-health-finalists-and-honorable-mentions |url-status=live}}</ref> 

* The Galien Foundation named Abbott’s FreeStyle Libre as Best Medical Technology within the last 50 years (1970–2020).<ref>{{Cite web |url=https://www.drugdeliverybusiness.com/abbott-freestyle-libre-best-medical-technology-galien-foundation/ |title=Abbott FreeStyle Libre named 'best medical technology' in last 50 years by Galien Foundation |first=Sean |last=Whooley|date=28 October 2022 |website=MassDevice|access-date=5 July 2023 |archive-date=5 July 2023 |archive-url=https://web.archive.org/web/20230705143104/https://www.drugdeliverybusiness.com/abbott-freestyle-libre-best-medical-technology-galien-foundation/ |url-status=live}}</ref>

* The company has been listed on the Seramount/''[[Working Mother]]''{{'}}s "100 Best Companies" list for 21 years in a row, named a top company for executive women by Seramount.<ref>{{cite news |url=https://seramount.com/best-companies/100-best-companies-winners-2022/ |title=2022 100 BEST COMPANIES WINNERS |work=Seramount |archive-date=13 February 2023|archive-url=https://web.archive.org/web/20230213200138/https://seramount.com/best-companies/100-best-companies-winners-2022/ |url-status=live}}</ref><ref>{{cite news |url=https://seramount.com/best-companies/2022-top-companies-for-executive-women-winners/ |title=2022 TOP COMPANIES FOR EXECUTIVE WOMEN WINNERS |work=Seramount |archive-date=13 February 2023 |archive-url=https://web.archive.org/web/20230213200135/https://seramount.com/best-companies/2022-top-companies-for-executive-women-winners/ |url-status=live}}</ref><ref>{{Cite web |url=https://www.workingmother.com/best-companies-abbott |title=Abbott |website=Working Mother |language=en |access-date=2020-04-02 |archive-date=10 August 2020 |archive-url=https://web.archive.org/web/20200810230107/https://www.workingmother.com/best-companies-abbott |url-status=live }}</ref>

* Included on ''[[Science (journal)|Science]]'' magazine's ''Top 20 Employers'' list.<ref>{{Cite web |url=https://www.science.org/content/article/top-employers-rapid-response-covid-19-diversity-and-innovation|title=2020's Top Employers: Rapid response to COVID-19, diversity, and innovation |website=Science Magazine|access-date=26 October 2021|archive-date=26 October 2021|archive-url=https://web.archive.org/web/20211026140237/https://www.science.org/content/article/top-employers-rapid-response-covid-19-diversity-and-innovation|url-status=live}}</ref> 

* Recognized as a top company by DiversityInc for diversity within the company for 19 consecutive years (2004–2022).<ref>{{cite web |url=https://www.diversityinc.com/company/abbott/ |title=2022 TOP 50 COMPANIES FOR DIVERSITY |website=DiversityInc |date=7 July 2023 | archive-date=13 February 2023 |archive-url=https://web.archive.org/web/20230213193855/https://www.diversityinc.com/company/abbott/ |url-status=live}}</ref>

* Included on the [[Dow Jones Sustainability Index]] for 18 consecutive years.<ref>{{cite news |url=https://www.bloomberg.com/press-releases/2021-11-15/abbott-achieves-highest-score-in-its-industry-for-the-ninth-consecutive-year-on-the-dow-jones-sustainability-index-djsi |title=Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI) |website=Bloomberg |date=15 November 2021 }}</ref>

==Products==
[[File:Box of Abbott Panbio COVID-19 antigen rapid AG nasal tests.jpg|thumb|Box of Abbott products]]
===Nutrition===
Pediatric nutrition products manufactured by Abbott Laboratories include:<ref name=10K/>
* Similac
* Similac Gain 
* Similac GainPlus 
* Similac GainSchool 
* Similac Neosure
* Similac Essencia
* Similac Tummicare HW
* Isomil
* Pedialyte
* PediaSure
* PediaSure Plus
* PediaSure Plus 10+

Adult nutrition products manufactured by Abbott Laboratories include:
* Ensure
* Ensure Gold
* Glucerna (Ensure Diabetes Care in India)
* Juven
* ZonePerfect

===Diagnostics===
Diagnostics products manufactured by Abbott include:<ref name=10K/>
* i-STAT (While intended for a human audience, the point of care analyzers also demonstrate utility for the veterinary profession<ref>{{Cite journal |last1=Smith|first1=Joseph (Joe) |last2=Varga |first2=Anita |last3=Schober |first3=Karsten E. |year=2020|title=Comparison of two commercially available immunoassays for the measurement of bovine cardiac troponin I in cattle with induced myocardial injury |journal=Frontiers in Veterinary Science |language=en |volume=7 |article-number=531 |doi=10.3389/fvets.2020.00531 |pmid=33062647 |pmc=7481330 |issn=2297-1769|doi-access=free}}</ref> and are marketed by Abaxis.)
* Alinity
* Architect
* IDNOW 
* Digival
* BinaxNOW<ref>{{Cite web |url=https://www.wsj.com/articles/choose-the-right-covid-19-test-for-your-needs-11629892800 |author=Betsy Morris |date=August 25, 2021 |title=Which Covid-19 Test Should You Get, Based on Your Needs |work=The Wall Street Journal |access-date=30 August 2021 |archive-date=30 August 2021 |archive-url=https://web.archive.org/web/20210830181241/https://www.wsj.com/articles/choose-the-right-covid-19-test-for-your-needs-11629892800 |url-status=live}}</ref>

===Medical devices===
[[Continuous glucose monitors]]:
* FreeStyle Libre
* FreeStyle Libre 2 Sensor 
* FreeStyle Libre 3 Sensor<ref>{{Cite web |title=Freestyle libre 3 Sensor |url=https://cgmmonitors.com/product/freestyle-libre-3-sensor/ |access-date=2022-08-19 |website=Cgm Monitors |archive-date=24 May 2023 |archive-url=https://web.archive.org/web/20230524164205/https://cgmmonitors.com/product/freestyle-libre-3-sensor/ |url-status=live }}</ref>

Cardiovascular devices manufactured by Abbott Laboratories include:<ref name=10K/>
* MitraClip
* Confirm Rx
* Amplatzer Piccolo Occluder
* Heartmate
* Xience
* CARDIOMEMS
* Gallant ICD
* CentriMag
* Aveir DR{{Efn|pacemaker, received FDA approval on July 5, 2023}}<ref name="aveirdr">{{cite web | url=https://www.msn.com/en-us/money/personalfinance/fda-gives-the-okay-for-abbott-s-new-minimally-invasive-pacemaker/ar-AA1dsBds | title=MSN | website=[[MSN]] }}</ref>

Neuromodulation devices manufactured by Abbott Laboratories include:
* BurstDR Technology
* FlexBurst360 Technology
* Proclaim DRG Neurostimulation System
* Infinity Deep Brain Stimulation System
* Proclaim XR Recharge-Free Spinal Cord Stimulator
* NT2000IX Radiofrequency Generator
* Proclaim Elite Recharge-Free SCS System
* Prodigy MRI SCS System

==Litigation and controversies==


===Use of double Irish arrangement and single malt tax to reduce taxation===
Before it was abolished, Abbott allegedly took advantage of the [[double Irish arrangement]] tax structure, a then-legal but controversial Irish taxation tool used by US multinationals to reduce US corporate taxes on non-U.S profits.<ref name="di"/> Abbott's Irish holding company, the Bermuda-resident Abbott Laboratories Vascular Enterprises (ALVE), employed no staff in 2017, but was responsible for distributing Abbot's products and licensing its technology worldwide.<ref name="di"/> ALVE was incorporated in 2003 and had a pre-tax profit of €2 billion in 2016 and 2017 on revenues of €5.2 billion; no taxation was paid on these profits.<ref name="di"/> ALVE had never filed accounts in Ireland since 2003 as it was structured as an [[unlimited liability company]] (ULC); however, new EU accounts directives required ALVE to file Irish accounts in 2018.<ref name="di"/> These accounts listed ALVE's registered office as the address of Ireland's largest tax-law firm, [[Matheson (law firm)|Matheson]], who have been identified with Double Irish tax structures for Microsoft and Google.<ref name="di">{{cite news |url=https://www.thejournal.ie/abbott-ireland-tax-avoidance-4528308-Mar2019/ |title=How the IDA's top client used Ireland to siphon billions offshore tax-free |newspaper=[[TheJournal.ie]] | first=Peter | last=Bodkin |date=19 March 2019 |archive-date=19 March 2019|archive-url=https://web.archive.org/web/20190319121457/https://www.thejournal.ie/abbott-ireland-tax-avoidance-4528308-Mar2019/ |url-status=live}}</ref><ref name="wsj">{{cite news | url=https://www.wsj.com/articles/dublin-moves-to-block-controversial-tax-gambit-1381890312 |title=Dublin Moves to Block Controversial Tax Gambit | first1=Damian | last1=Paletta| first2=Kate | last2=Linebaugh | newspaper=[[The Wall Street Journal]] |date=15 October 2013 |archive-date=16 June 2018 |archive-url=https://web.archive.org/web/20180616203914/https://www.wsj.com/articles/dublin-moves-to-block-controversial-tax-gambit-1381890312|url-status=live}}</ref>

In September 2021, the ''[[Irish Times]]'' reported that Abbott was using the [[Single malt tax]] structure to shield profits on its [[COVID-19 testing]] kits.<ref name=abbotlabs>{{cite news | newspaper=[[The Irish Times]] | url=https://www.irishtimes.com/news/health/pharma-giant-abbott-using-irish-single-malt-scheme-to-avoid-tax-on-profits-1.4674126 | title=Pharma giant Abbott using Irish 'single-malt' scheme to avoid tax on profits | first1=Pat | last1=Leahy | date=15 September 2021 | accessdate=16 September 2021 | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915040424/https://www.irishtimes.com/news/health/pharma-giant-abbott-using-irish-single-malt-scheme-to-avoid-tax-on-profits-1.4674126 | url-status=live }}</ref><ref>{{cite news | first=Cliff | last=Taylor | newspaper=[[The Irish Times]] | date=15 September 2021 | url=https://www.irishtimes.com/business/economy/how-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058 | title=How Abbott Labs devised its formula for 'single Malt' taxation | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915213227/https://www.irishtimes.com/business/economy/how-abbott-labs-devised-its-formula-for-single-malt-taxation-1.4674058 | url-status=live }}</ref>

=== Leuprorelin ===
In October 2001, the US Department of Justice, states attorneys general, and TAP Pharmaceutical Products, a subsidiary of Abbott Laboratories, settled criminal and civil charges against TAP related to federal and state [[Medicare fraud]] and illegal marketing of the drug [[leuprorelin]].<ref>{{Cite journal |last=Charatan |first=Fred|date=2001-10-13|title=Drug companies defrauded Medicare of millions |journal=BMJ: British Medical Journal |volume=323 |issue=7317 |pages=828 |doi=10.1136/bmj.323.7317.828a |issn=0959-8138 |pmc=1121385 |pmid=11597964}}</ref> TAP paid a total of $875 million, a [[List of largest pharmaceutical settlements|record high pharmaceutical settlement]].<ref name=":1">{{Cite news |last=Petersen |first=Melody |date=2001-10-04 |title=2 Drug Makers to Pay $875 Million to Settle Fraud Case |language=en-US |work=The New York Times |url=https://www.nytimes.com/2001/10/04/business/2-drug-makers-to-pay-875-million-to-settle-fraud-case.html |access-date=2022-01-24|issn=0362-4331}}</ref><ref name=":2">{{Cite web |title=#513: 10-03-01 TAP PHARMACEUTICAL PRODUCTS INC. AND SEVEN OTHERS CHARGED WITH HEALTH CARE CRIMES COMPANY AGREES TO PAY $875 MILLION TO SETTLE CHARGES |url=https://www.justice.gov/archive/opa/pr/2001/October/513civ.htm|access-date=2022-01-24 |website=www.justice.gov|archive-date=11 November 2020|archive-url=https://web.archive.org/web/20201111201014/https://www.justice.gov/archive/opa/pr/2001/October/513civ.htm |url-status=live}}</ref> This comprised $290 million for violating the Prescription Drug Marketing Act, $559.5 million to settle federal fraud charges for overcharging Medicare, and $25.5 million reimbursement to 50 states and Washington, D.C., for filing false claims with the states' Medicaid programs.<ref name=":2" /> The case arose under the [[False Claims Act]] with claims filed by Douglas Durand, a former TAP vice president of sales, and Joseph Gerstein, a doctor at [[Tufts University]]'s HMO practice.<ref name=":1" /> Durand, Gerstein, and Tufts shared $95 million of the settlement.<ref name=":1" />

There have since been various suits concerning leuprorelin use, none successful.<ref>{{Cite web |date=2021-05-08 |title=What You Should Know About Lupron Class Action Lawsuit |url=https://lawanswer.org/what-you-should-know-about-lupron-class-action-lawsuit/ |access-date=2022-02-28 |website=Law Answer |language=en-US |archive-date=28 February 2022 |archive-url=https://web.archive.org/web/20220228112017/https://lawanswer.org/what-you-should-know-about-lupron-class-action-lawsuit/ |url-status=live }}</ref><ref>{{Cite web |title=Abbott, AbbVie Defeat Long-Running Lupron Bone, Joint Suit (1) |url=https://news.bloomberglaw.com/product-liability-and-toxics-law/abbott-abbvie-defeat-long-running-lupron-bone-joint-lawsuit |access-date=2022-02-28 |website=news.bloomberglaw.com |date=29 September 2021 |language=en |archive-date=28 February 2022 |archive-url=https://web.archive.org/web/20220228112014/https://news.bloomberglaw.com/product-liability-and-toxics-law/abbott-abbvie-defeat-long-running-lupron-bone-joint-lawsuit |url-status=live }}</ref> These lawsuits have focused on either the over-prescription of the drug or the lack of warnings about its potential [[Leuprorelin#Side effects|side effects]]. Between 2010 and 2013, the FDA updated the Lupron drug label to include new safety information on the risk of thromboembolism, loss of bone density and convulsions.<ref>{{Cite web |date=2019-02-12 |title=More women come forward with complaints about Lupron side effects |url=https://www.ktnv.com/news/investigations/more-women-come-forward-with-complaints-about-lupron-side-effects |access-date=2022-02-28 |website=KTNV |language=en}}</ref> The FDA then said that the benefits of leuprorelin outweighed its risks when used according to its approved labeling. From 2017 the FDA evaluated leuprorelin's connection to pain and discomfort in musculoskeletal and connective tissue.<ref>{{Cite web |title=January - March 2017 {{!}} Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS) |date=3 January 2023 |url=https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/january-march-2017-potential-signals-serious-risksnew-safety-information-identified-fda-adverse |publisher=FDA |language=en |access-date=28 February 2022 |archive-date=28 February 2022 |archive-url=https://web.archive.org/web/20220228112016/https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/january-march-2017-potential-signals-serious-risksnew-safety-information-identified-fda-adverse |url-status=dead }} With updates; last update 6 January 2023.</ref>

===Humira===
In March 2003, British company Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" ([[Adalimumab]]) with Abbott Laboratories in the High Court of London. In December 2004, the judgment ruled for CAT.<ref>{{cite web |url=https://www.bloomberg.com/apps/news?pid=newsarchive&sid=af.37juYEPaQ |title=Cambridge Antibody Wins Lawsuit Against Abbott Labs (Update5) – Bloomberg |website=[[Bloomberg News]] |date=16 July 2023 |access-date=5 March 2017 |archive-date=24 September 2015 |archive-url=https://web.archive.org/web/20150924173217/http://www.bloomberg.com/apps/news?pid=newsarchive&sid=af.37juYEPaQ |url-status=live }}</ref>

Abbott was required to pay CAT US$255 million in lieu of royalties the MRC, the Scripps Research Institute and Stratagene would have received on sales of Humira after December 2004. Some of this sum was to be passed to its partners in development, including US$191 million for the [[Medical Research Council (United Kingdom)|UK Medical Research Council]] (MRC), plus a further $7.5 million over five years from 2006 providing that Humira remained on the market.<ref>{{Cite web |date=2005-10-26 |title=MRC to receive over USD200m |url=https://www.lifearc.org/news/2005/mrc-to-receive-over-usd200m/ |access-date=2022-02-28 |website=LifeArc |language=en-GB |archive-date=27 September 2022 |archive-url=https://web.archive.org/web/20220927170442/https://www.lifearc.org/news/2005/mrc-to-receive-over-usd200m/ |url-status=live }}</ref>

=== Operation Headwaters ===
In October 2003, Abbott Laboratories and two of its units agreed to pay a total of $600 million in the first combined civil settlement and criminal conviction for offering kickbacks to agents of "Operations Headwaters", an undercover investigation by the FBI.<ref>{{Cite web|title=#613: 11-10-03 JUSTICE DEPT. CIVIL FRAUD RECOVERIES TOTAL $2.1 BILLION FOR FY 2003 FALSE CLAIMS ACT RECOVERIES EXCEED $12 BILLION SINCE 1986|url=https://www.justice.gov/archive/opa/pr/2003/November/03_civ_613.htm|access-date=2022-01-24|website=www.justice.gov|archive-date=24 January 2022|archive-url=https://web.archive.org/web/20220124195613/https://www.justice.gov/archive/opa/pr/2003/November/03_civ_613.htm|url-status=live}}</ref>

===Depakote===
On 2 October 2012, the company was charged with a $500 million fine and $198.5 million forfeiture for illegal marketing of [[Depakote]] for uses not approved by the FDA. The court also sentenced Abbott to a five-year term of probation and court supervision.<ref name="doj">[https://www.justice.gov/opa/pr/2012/May/12-civ-585.html Abbott Labs to Pay $1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote] {{Webarchive|url=https://web.archive.org/web/20140821040621/http://www.justice.gov/opa/pr/2012/May/12-civ-585.html |date=21 August 2014 }}, Press Release, [[United States Department of Justice]] Office of Public Affairs, 7 May 2012. Retrieved 17 August 2014.</ref> Shareholders then brought derivative suits against the company directors for breach of fiduciary duty.<ref>U.S. ex rel. McCoyd v. Abbott Laboratories, 1:07-cv-00081 (W.D. Va.); U.S. ex rel. Mulcahy v. Abbott Laboratories, 1:08-cv-0054 (W.D. Va.); U.S. ex rel. Dietzler v. Abbott Laboratories, 1:09-cv-00051 (W.D. Va.); U.S. ex rel. Spetter v. Abbott Laboratories, 1:10-cv-00006 (W.D. Va.).</ref><ref>{{Cite web|url=https://www.law360.com/articles/516296/abbott-shareholders-agree-to-settle-depakote-marketing-suit|title=Abbott, Shareholders Agree To Settle Depakote Marketing Suit - Law360|website=www.law360.com|access-date=5 July 2023|archive-date=4 March 2016|archive-url=https://web.archive.org/web/20160304072158/http://www.law360.com/articles/516296/abbott-shareholders-agree-to-settle-depakote-marketing-suit|url-status=live}}</ref> Following Abbott's spinoff of its research-based pharmaceuticals business, it no longer owns the commercial rights and associated responsibilities for Humira and Depakote.<ref>{{cite news|url=https://www.reuters.com/article/abbott/update-2-abbott-ultra-bullish-on-humira-despite-spinoff-plan-idUSN1E79K06F20111021|title=Abbott ultra-bullish on Humira despite spinoff plan|work=Reuters|date=21 October 2011|last1=Krauskopf|first1=Ransdell Pierson|access-date=22 November 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820201630/https://www.reuters.com/article/abbott/update-2-abbott-ultra-bullish-on-humira-despite-spinoff-plan-idUSN1E79K06F20111021|url-status=live}}</ref>

=== Glucose monitors ===
In 2021, two of Abbott Laboratories' subsidiaries, Arriva Medical LLC and Alere Inc, had to pay $160m to resolve claims that they had fraudulently billed [[Medicare (United States)|Medicare]] for glucose monitors. The [[US Department of Justice]] said that Arriva used free glucose monitors to induce patients to order more consumable supplies, then took [[Kickback (bribery)|kickback]]s on the increased sales. The company was also accused of charging Medicare for glucose monitors given to patients who were ineligible, or even dead.<ref>{{Cite news|last=Stempel|first=Jonathan|date=2021-08-02|title=Abbott Labs to pay $160 mln over kickbacks, false diabetes claims to Medicare|language=en|work=Reuters|url=https://www.reuters.com/business/healthcare-pharmaceuticals/us-says-abbott-units-pay-160-mln-resolve-alleged-false-medicare-claims-2021-08-02/|access-date=2022-01-24|archive-date=24 January 2022|archive-url=https://web.archive.org/web/20220124011240/https://www.reuters.com/business/healthcare-pharmaceuticals/us-says-abbott-units-pay-160-mln-resolve-alleged-false-medicare-claims-2021-08-02/|url-status=live}}</ref>

=== Plant shutdown ===
In February 2022, Abbott recalled baby formulas from the market and shut down their Michigan plant after complaints of illness and death in infants caused by serious bacterial infections. Following Abbotts' meeting the initial requirement of the [[U.S. Food & Drug Administration]], the facility reopened in June 2022.<ref>{{Cite news |date=2022-05-17 |title=Explainer: What happened with Abbott baby formula that worsened a U.S. shortage? |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/what-happened-with-abbott-baby-formula-that-worsened-us-shortage-2022-05-16/ |access-date=2022-06-04 |archive-date=4 June 2022 |archive-url=https://web.archive.org/web/20220604180124/https://www.reuters.com/business/healthcare-pharmaceuticals/what-happened-with-abbott-baby-formula-that-worsened-us-shortage-2022-05-16/ |url-status=live }}</ref><ref>{{Cite news |last1=Aboulenein |first1=Ahmed |last2=Heavey |first2=Susan |date=2022-05-19 |title=U.S. FDA says Abbott baby formula plant on track to reopen in 1-2 weeks |language=en |work=Reuters |url=https://www.reuters.com/business/retail-consumer/abbott-baby-formula-plant-track-reopen-within-1-2-weeks-fda-commissioner-2022-05-19/ |access-date=2022-06-04}}</ref><ref>{{Cite news |date=2022-06-04 |title=Baby formula shortage could ease as Abbott reopens Michigan plant |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-reopens-baby-formula-plant-michigan-2022-06-04/ |access-date=2022-06-04}}</ref><ref>{{Cite web |title=Abbott baby formula aftermath: One dead child and another with brain damage so bad she has constant seizures and crying bouts |url=https://fortune.com/well/2023/12/08/abbott-baby-formula-recall-dead-child-brain-damage/ |access-date=2024-03-18 |website=Fortune Well |language=en |archive-date=18 March 2024 |archive-url=https://web.archive.org/web/20240318173113/https://fortune.com/well/2023/12/08/abbott-baby-formula-recall-dead-child-brain-damage/ |url-status=live }}</ref>

=== Deep Brain Stimulation Device Recall ===
On July 18, 2023, Abbott recalled its Proclaim and Infinity IPGs due to complaints from patients who are unable to exit MRI mode. The use of the affected IPGs may require surgery to remove the device and replace it with a new device.

There have been 186 reported incidents and 73 reported injuries. There have been no reports of death.<ref>{{Cite journal |last=Health |first=Center for Devices and Radiological |date=2023-09-13 |title=Abbott Medical Recalls Proclaim and Infinity IPGs for Inability to Exit Magnetic Resonance Imaging (MRI) Mode |url=https://www.fda.gov/medical-devices/medical-device-recalls/abbott-medical-recalls-proclaim-and-infinity-ipgs-inability-exit-magnetic-resonance-imaging-mri-mode |journal=FDA |language=en |access-date=22 September 2023 |archive-date=20 September 2023 |archive-url=https://web.archive.org/web/20230920082218/https://www.fda.gov/medical-devices/medical-device-recalls/abbott-medical-recalls-proclaim-and-infinity-ipgs-inability-exit-magnetic-resonance-imaging-mri-mode |url-status=dead }}</ref> Noted by Gita Amar, a PR representative for Abbott Laboratories on this issue. "The company has communicated this action to physicians and regulatory bodies. No products need to be returned to the company or replaced."<ref>{{Cite web |date=2023-09-13 |title=Abbott Recalls Certain Proclaim, Infinity Neurostimulation Devices |url=https://wallstreetwaves.com/abbott-recalls-certain-proclaim-infinity-neurostimulation-devices/ |access-date=2023-09-22 |language=en-US |archive-date=28 October 2023 |archive-url=https://web.archive.org/web/20231028173116/https://wallstreetwaves.com/abbott-recalls-certain-proclaim-infinity-neurostimulation-devices/ |url-status=live }}</ref>

=== Necrotizing Enterocolitis (NEC) Lawsuit ===
On July 26, 2024, a jury ordered Abbott Laboratories to pay $495 million in the case of Margo Gill vs. Abbott Laboratories, comprising $95 million in compensatory damages and $400 million in punitive damages.<ref>{{Cite web |date=2025-04-03 |title=TorHoerman Law Obtains $495 Million NEC Verdict as Lead Counsel in Infant Formula NEC Trial Against Abbott Laboratories |url=https://www.torhoermanlaw.com/toxic-baby-formula-nec-lawsuit/495-million-verdict-obtained-by-torhoerman-law-as-lead-counsel-in-infant-formula-nec-trial-against-abbott-laboratories/ |access-date=2025-04-03 |website=TorHoerman Law, LLC |language=en}}</ref> The lawsuit alleged that Abbott's infant formula for premature babies increased the risk of [[necrotizing enterocolitis]] (NEC), a gastrointestinal disease that can cause intestinal tissue death and can be life-threatening.

==Sponsorship==
In 2015 Abbott became the title sponsor of the [[World Marathon Majors]].<ref name=Marathon>{{cite web|title=ABBOTT CELEBRATES THE POWER OF HEALTH AND ACHIEVEMENT AS FIRST-EVER TITLE SPONSOR OF WORLD MARATHON MAJORS|url=https://www.worldmarathonmajors.com/news/wmm/show/abbott-celebrates-the-power-of-health-and-achievement-as-first-ever-title-sponsor-of-world-marathon/|publisher=World Marathon Majors|access-date=10 November 2015|archive-url=https://web.archive.org/web/20160304112827/https://www.worldmarathonmajors.com/news/wmm/show/abbott-celebrates-the-power-of-health-and-achievement-as-first-ever-title-sponsor-of-world-marathon/|archive-date=4 March 2016|url-status=dead}}</ref>

==See also==
* [[List of Illinois companies]]
* [[List of largest biomedical companies by market capitalization]]
* [[List of pharmaceutical companies]]
* [[Clara Abbott]]
* [[2022 United States infant formula shortage]]

==Notes==
{{notelist}}

==References==
{{Reflist|}}

==External links==
{{Commons category}}
* {{Official website|https://www.abbott.com}}
{{Finance links
| name = Abbott Laboratories
| google = ABT:NYSE
| reuters = ABT
| sec_cik = 1800
| yahoo = ABT
}}

{{Illinois Corporations}}
{{Pharmaceutical companies of the United States}}
{{Portal bar|Companies|Illinois}}
{{authority control}}

{{coord|42.30175|-87.89595|dim:3000_region:US-IL|display=title}}

[[Category:Abbott Laboratories| ]]
<!--at july 2013, not further diffused because prose silent on state where established-->
[[Category:1888 establishments in Illinois]]
[[Category:1920s initial public offerings]]
[[Category:American companies established in 1888]]
[[Category:Biotechnology companies of the United States]]
[[Category:Companies based in Lake County, Illinois]]
[[Category:Companies in the KSE 100 Index]]
[[Category:Companies in the S&P 500 Dividend Aristocrats]]
[[Category:Companies listed on the New York Stock Exchange]]
[[Category:Lake Bluff, Illinois]]
[[Category:Life sciences industry]]
[[Category:Medical device manufacturers]]
[[Category:Multinational companies headquartered in the United States]]
[[Category:Multinational health care companies]]
[[Category:Pharmaceutical companies established in 1888]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Veterinary medicine companies]]
[[Category:Veterinary medicine in the United States]]